Date Range
Date Range
Date Range
This website uses cookies to collect statistical information on the use of our website with the goal of improving user experience. Read our cookie policy for more information. Click here to accept the use of cookies on our website.
You are about to enter another country or region-specific website. Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on products or uses of those products that are not approved in other countries or regions. Do you wish to continue and exit this website? We have detected that you may be viewing the site from the United States.
Please log in using your username and password provided by our client service team. For support relating to logins, please contact our client service team.
Annual Reports and Proxy Statements. Gentex develops high-value safety and technology products that make the world a safer, simpler, and smarter place. Gentex is committed to continuing to deliver shareholder value by developing advanced electronic products and features for the automotive, aerospace and fire protection industries.
Investing in first-in-class cancer therapeutics. ASH 2014 Investor and Analyst Event. Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Geron Corporation Reports Second Quarter 2015 Financial Results. Geron Corporation Reports First Quarter 2015 Financial Results and Recent Events.